Skip to main content

Research Repository

Advanced Search

Outputs (18)

Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma (2022)
Journal Article
Fu, R., Norris, G. A., Willard, N., Griesinger, A. M., Riemondy, K. A., Amani, V., Grimaldo, E., Harris, F., Hankinson, T. C., Mitra, S., Ritzmann, T. A., Grundy, R. R., Foreman, N. K., & Donson, A. M. (2023). Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma. Neuro-Oncology, 25(4), 786-798. https://doi.org/10.1093/neuonc/noac219

Background The diverse cellular constituents of childhood brain tumor ependymoma, recently revealed by single cell RNA-sequencing, may underly therapeutic resistance. Here we use spatial transcriptomics to further advance our understanding of the tum... Read More about Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.

Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol (2022)
Journal Article
Leblond, P., Massimino, M., English, M., Ritzmann, T. A., Gandola, L., Calaminus, G., Thomas, S., Pérol, D., Gautier, J., Grundy, R. G., & Frappaz, D. (2022). Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. Frontiers in Neurology, 13, Article 887544. https://doi.org/10.3389/fneur.2022.887544

Background: The clinical management of ependymoma in childhood and adolescence is complex and the clinicobiopathological correlates of outcome remain poorly understood. This international SIOP Ependymoma II (SIOP EPII) trial aims to improve the outco... Read More about Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol.

Recurrent ACVR1 mutations in posterior fossa ependymoma (2022)
Journal Article
Pratt, D., Lucas, C.-H. G., Selvam, P. P., Abdullaev, Z., Ketchum, C., Quezado, M., Armstrong, T. S., Gilbert, M. R., Papanicolau-Sengos, A., Raffeld, M., Choo-Wosoba, H., Chan, P., Whipple, N., Nasrallah, M., Santi, M., Ramaswamy, V., Giannini, C., Ritzmann, T. A., Grundy, R. G., Burford, A., …Aldape, K. (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 144, 373-376. https://doi.org/10.1007/s00401-022-02435-2

Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04) (2022)
Journal Article
Apps, J. R., Maycock, S., Ellison, D. W., Jaspan, T., Ritzmann, T. A., Macarthur, D., Mallucci, C., Wheatley, K., Veal, G. J., Grundy, R. G., & Picton, S. (2022). Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04). Neuro-Oncology Advances, 4(1), Article vdac053. https://doi.org/10.1093/noajnl/vdac053

Background
Relapsed ependymoma has a dismal prognosis, and the role of chemotherapy at relapse remains unclear. This study prospectively evaluated the efficacy of intensive intravenous (IV) etoposide in patients less than 21 years of age with relaps... Read More about Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04).

SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study (2022)
Journal Article
Ritzmann, T. A., Chapman, R. J., Kilday, J.-P., Thorp, N., Modena, P., Dineen, R. A., Macarthur, D., Mallucci, C., Jaspan, T., Pajtler, K. W., Giagnacovo, M., Jacques, T., Paine, S., Ellison, D., Bouffet, E., & Grundy, R. G. (2022). SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study. Neuro-Oncology, 24(6), 936–948. https://doi.org/10.1093/neuonc/noac012

Background
SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3 to 21 years treated with a staged management strategy. A further aim was to asses... Read More about SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study.

Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic (2021)
Journal Article
Williams, G., McLean, R., Liu, J. F., Ritzmann, T. A., Dandapani, M., Shanmugavadivel, D., Sachdev, P., Brougham, M., Mitchell, R. T., Conway, N. T., Law, J., Cunnington, A., Ogunnaike, G., Brougham, K., Bayman, E., & Walker, D. (2021). Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic. BMJ Paediatrics Open, 5(1), Article e001078. https://doi.org/10.1136/bmjpo-2021-001078

Background The COVID-19 pandemic led to changes in patterns of presentation to emergency departments. Child health professionals were concerned that this could contribute to the delayed diagnosis of life-threatening conditions, including childhood ca... Read More about Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic.

EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY (2021)
Journal Article
Ritzmann, T. A., Chapman, R. J., Macarthur, D., Mallucci, C., Kilday, J.-P., Thorp, N., Modena, P., Giagnacovo, M., Dineen, R., Jaspan, T., Pajtler, K. W., Jacques, T. S., Paine, S. M. L., Ellison, D. W., Bouffet, E., & Grundy, R. G. (2021). EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY. Neuro-Oncology, 23(Supplement 1), i14. https://doi.org/10.1093/neuonc/noab090.054

Introduction
Surgery and radiotherapy are established childhood ependymoma treatments. The efficacy of chemotherapy has been debated. We report final results of the SIOP Ependymoma I trial, with 12-year follow-up, in the context of a post-hoc analys... Read More about EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY.

EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA (2021)
Journal Article
Donson, A., Ritzmann, T., Willard, N., Griesinger, A., Amani, V., Harris, F., Grimaldo, E., Sanford, B., Riemondy, K., Hankinson, T., Grundy, R., & Foreman, N. (2021). EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 23(Supplement 1), i15-i16. https://doi.org/10.1093/neuonc/noab090.061

Ependymoma (EPN) of childhood is curable in only 50% of cases, with recurrences in the remainder that are refractory to treatment. In recent years significant advances have been made in understanding the molecular and cellular biology of EPN. Recent... Read More about EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA.

EPEN-08. THE TREM1 POSITIVE HYPOXIC MYELOID SUBPOPULATION IN POSTERIOR FOSSA EPENDYMOMA (2021)
Journal Article
Willard, N., Donson, A., Ritzmann, T., Grundy, R., Jackson, A., Hankinson, T., Griesinger, A., & Foreman, N. (2021). EPEN-08. THE TREM1 POSITIVE HYPOXIC MYELOID SUBPOPULATION IN POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 23(Supplement 1), i15. https://doi.org/10.1093/neuonc/noab090.058

We have previously shown the importance of immune factors in posterior fossa ependymoma (PF EPN). Recently, we found eight transcriptionally unique subpopulations of myeloid cells infiltrating PF EPN with one population particularly enriched in PFA1... Read More about EPEN-08. THE TREM1 POSITIVE HYPOXIC MYELOID SUBPOPULATION IN POSTERIOR FOSSA EPENDYMOMA.

EPEN-07. SINGLE-CELL RNA SEQUENCING IDENTIFIES A UNIQUE MYELOID SUBPOPULATION ASSOCIATED WITH MESENCHYMAL TUMOR SUBPOPULATION IN POOR OUTCOME PEDIATRIC EPENDYMOMA (2021)
Journal Article
Griesinger, A., Riemondy, K., Donson, A., Willard, N., Prince, E., Harris, F., Amani, V., Grimaldo, E., Hankinson, T., Grundy, R., Jackson, A., Foreman, N., & Ritzmann, T. (2021). EPEN-07. SINGLE-CELL RNA SEQUENCING IDENTIFIES A UNIQUE MYELOID SUBPOPULATION ASSOCIATED WITH MESENCHYMAL TUMOR SUBPOPULATION IN POOR OUTCOME PEDIATRIC EPENDYMOMA. Neuro-Oncology, 23(Supplement 1), i14-i15. https://doi.org/10.1093/neuonc/noab090.057

We have previously shown immune gene phenotype variations between posterior fossa ependymoma subgroups. PFA1 tumors chronically secrete IL-6, which induces secretion of myeloid cell IL-8 and pushes the infiltrating myeloid cells to an immune suppress... Read More about EPEN-07. SINGLE-CELL RNA SEQUENCING IDENTIFIES A UNIQUE MYELOID SUBPOPULATION ASSOCIATED WITH MESENCHYMAL TUMOR SUBPOPULATION IN POOR OUTCOME PEDIATRIC EPENDYMOMA.